Publications

Hertz DL, McShane LM, Hayes DF, Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. J Clin Oncol. 2022;24(10):02209. doi: 10.1200/JCO.21.02209. [Epub ahead of print] PubMed PMID: 35324346.

Chen CS, Kim J, Garg N, Guntupalli H, Jagsi R, Griggs JJ, Sabel M, Dorsch MP, Callaghan B, Hertz DL. Chemotherapy-induced peripheral neuropathy detection via smartphone app: a cross-sectional pilot study. JMIR Mhealth Uhealth 2021;9(7):e27502  doi: 10.2196/27502

Hertz DL, Kidwell KM, Vangipuram K*, Li F, Pai MP, Burness ML, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Smith EM, Henry NL. Paclitaxel Plasma Concentration After the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res. 2018 Apr 27. pii: clincanres.0656.2018. doi: 10.1158/1078-0432.CCR-18-0656. [Epub ahead of print] PubMed PMID: 29703818.

Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech L, Loprinzi CL, Ruddy KJ, Lustberg M.  Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treat Rev. 2021 Jun 9;99:102241. doi: 10.1016/j.ctrv.2021.102241. [Epub ahead of print] Review. PubMed PMID: 34174668.

Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens ST, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 1;22(19):4890-4900. Epub 2016 May 3.

Mc Laughlin AM, Helland T^, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL, On behalf of the CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clin Pharmacol Ther. 2024 Mar 18;. doi: 10.1002/cpt.3238. [Epub ahead of print] PubMed PMID: 38494911.

Chen CS, Zirpoli G, Barlow WE, Budd GT, McKiver B, Pusztai L, Hortobagyi GN, Albain KS, Damaj MI, Godwin AK, Thompson A, Henry NL, Ambrosone CB, Stringer KA, Hertz DL.  Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. J Natl Compr Canc Netw. 2023 Nov;21(11):1172-1180.e3. doi: 10.6004/jnccn.2023.7062. PubMed PMID: 37935109; PubMed Central PMCID: PMC10976748.

Baker S, Brooks G, Dahut B, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper T, McLeod HL, O’Donnell P, Relling MV, Rudek M, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko C. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. PubMed PMID: 36821823; PubMed Central PMCID: PMC10414691.

Hertz DL. Assessment of the Clinical Utility of Pretreatment DPYD Testing for Patients Receiving Fluoropyrimidine Chemotherapy. J Clin Oncol. 2022 Nov 20;40(33):3882-3892. doi: 10.1200/JCO.22.00037. Epub 2022 Sep 15. PubMed PMID: 36108264.